News

  • NovaMechanics' researchers have identified computationally using Enalos Cheminformatics Tools, two new dual inhibitors of TNF and RANKL. These inhibitors can be further optimized to develop improved treatments for a range of inflammatory, autoimmune, and bone loss diseases The study published  in PLoS Computational Biology, entitled “Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)”. The study has been highlighted in EurekaAlert, Rheumatoid Arthritis News, Multiple Sclerosis News Today and IBD News Today. (May 2017)
  • Enalos Cloud Platform IDs two molecules that inhibit proteins involved in chronic inflammatory disease (more info) (April 2017)
  • Health Medicine Network: Scientists ID two molecules that inhibit proteins involved in chronic inflammatory disease (more info) (April 2017)